Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/10/20
Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/20
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020GlobeNewsWire • 07/30/20
The Secondary Impact Of COVID-19 Pandemic Leads To Bigger Market Potential For Axsome TherapeuticsSeeking Alpha • 07/27/20
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive DisorderGlobeNewsWire • 07/13/20
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease AgitationGlobeNewsWire • 06/26/20
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20